Eli Lilly Plans Global Expansion of Weight-Loss Drug

Eli Lilly Plans Global Expansion of Weight-Loss Drug

Expansion into Major Emerging Markets

Eli Lilly plans to launch its diabetes and weight-loss drug in major emerging markets, including India, Brazil, and Mexico, in the second half of 2025. The company is increasing its production capacity to meet growing demand.

Market Opportunity and Demand

Global demand for weight-loss drugs has surged, presenting a significant market opportunity. The targeted countries have large populations and rising obesity rates, making them key growth areas.

Chief Financial Officer Lucas Montarce highlighted the potential, stating that around 900 million patients could benefit from the drug. He emphasized that these new market entries would drive substantial growth into late 2025 and beyond.

Planned Rollout and Timeline

Lilly aims to introduce the drug in India as early as 2025. The drug is currently available in the UK and Europe under the same brand name for both diabetes and weight loss, while in the U.S., it is marketed separately for obesity.

Expansion in China

Lilly had a limited launch of the drug in China last year and plans a broader rollout this year. Competitor Novo Nordisk launched a similar obesity drug in China in late 2023, signaling strong market competition.

Manufacturing Investments and Global Production

Since 2020, Lilly has committed over $23 billion to scaling up its manufacturing capabilities worldwide. The company operates plants in the U.S., Ireland, Italy, and Spain to support increased production and supply.

Revenue Forecast

Lilly projects total sales to be between $58 billion and $61 billion in 2025, reflecting strong growth expectations from its weight-loss and diabetes drug expansion.

“Eli Lilly Plans Global Expansion of Weight-Loss Drug” “Eli Lilly Plans Global Expansion of Weight-Loss Drug”